Hanson Wade Group have taken the decision to cancel this meeting. Please do accept our apologies for any inconvenience or disappointment this will cause. Please register your interest here if you would like updates on the meeting or topic.
Exploring Novel Hallmark of Aging Targeting Strategies & Defining Quantitative Endpoints to Enhance Translatability & Clinical Success
Age-related disease biotechs are set to shine in 2024, but to successfully navigate the volatile market of 2024, rapid proof-of-concept studies and validated clinical endpoints are crucial for funding and pipeline progress.
The 6th Age-Related Disease Therapeutics Summit is the only industry-led meeting for longevity biotechs to demonstrate clinically validated data to large pharma and investors to form commercial long-term partnerships, and together propel late stage commercialization.
Explore biomarkers, navigate regulatory pathways, and foster collaborations for pipeline support and commercialization.
Gain unparalleled competitive intelligence, scientific advancements and form meaningful partnerships with those solving humankind’s fundamental problem.
60+
Attendees
1
Exclusive Workshop Day
20+
Expert Speakers
3
Content Filled Days
Investors
Biotechs
Large Pharma
“The breadth and depth of the presentations was outstanding. There was little repetition whilst remaining entirely on point with respect to the mechanisms underlying aging and longevity. Absolutely outstanding speakers.”
Marilda Chung, Cureline, Inc.
“The quality of presentations and discussions led to a standout, enjoyable experience.”
Rosaly Correa-de-Auraujo, National Institute of Aging
Previously Attending Companies Include:
Other Events in the Series:
